NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries Singapore, June 6, 2022, Moleac is pleased to announce the release of the results of the SATURN study1 published online in the Journal of Spinal Cord Medicine. SATURN study aimed at...
NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results,...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals. Moleac is dedicated in finding, developing, and commercializing new...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug...
ESOC 2020: Abstracts on NeuroAiD In November 2020, ESO-WSO provided scientific updates to Health Care Practitioners. During this conference, 4 abstracts on NeuroAiD’s safety and efficacy in post-stroke recovery are presented by international speakers....
World Stroke Day 2020 Stroke remains one of the main cause for disability worldwide. Moleac remains committed to helping patients Reconnect with their loved ones. We always place patients at the center of everything we do, and their journey towards full recovery is...
